Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: #ASCO18: Mixed reaction to Nektar’s ‘confusing’ NKTR-214 trial .Nektar Therapeutics’ much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo seem to … Continue reading
Cet article #news #biotech #ASCO18: Mixed reaction to Nektar’s ‘confusing’ NKTR-214 trial est apparu en premier sur Biotech 365.